Company Overview
Snapshot
Founded in May 2008 by Maor Sasson, Doron Eisenstadt, and Ofra Chen, TransAlgae operates with 11–50 employees. The company has raised a total of $29.52 million across 6 funding rounds from 2 investors. In March 2021, TransAlgae signed an exclusive business development collaboration agreement with Virbac to develop a vaccine based on its microalgae-based oral delivery technology.
Business overview
TransAlgae develops an innovative algae-based platform for the oral delivery of drugs, including vaccines, immune modulators, and insecticides. This technology is designed for applications in human and animal health, as well as crop protection. The company's core product leverages genetically modified algae for bio-encapsulation, enabling the oral delivery of therapeutic proteins. TransAlgae serves the pharmaceutical, animal health, and agriculture industries, offering solutions that aim to replace traditional methods like injections and chemical pesticides with more sustainable and efficient alternatives.
Strategic signal
In April 2021, TransAlgae secured an additional $2.5 million in investment from Gan Shmuel Foods, contributing to an ongoing $27 million fundraising round. This capital infusion signals strong investor confidence in TransAlgae's proprietary algae-based oral drug delivery technology and its potential to disrupt multiple sectors, including human pharmaceuticals, animal health, and crop protection. The continued investment validates the company's progress and its strategic market positioning.
Log in to access full profile ›Company Intelligence Q&A
- What is TransAlgae's core technology?
- TransAlgae develops an algae-based platform for the oral delivery of drugs, including vaccines, immune modulators, and insecticides, for human and animal health and crop protection. This technology utilizes genetically modified algae for native bio-encapsulation and effective oral delivery.
- What was a significant recent partnership for TransAlgae?
- In March 2021, TransAlgae signed an exclusive business development collaboration agreement with Virbac, a leading animal health company. This partnership aims to develop a vaccine based on TransAlgae's microalgae-based oral delivery technology, providing an effective and industrialized vaccination method.
- How much funding has TransAlgae raised in total?
- TransAlgae has raised a total of $29.52 million across 6 funding rounds from Gan Shmuel Foods and one other investor.
- Which investor recently participated in a funding round for TransAlgae?
- In April 2021, Gan Shmuel Foods invested an additional $2.5 million in TransAlgae. This investment was part of a larger $27 million fundraising round the company was undertaking.
- What are the applications of TransAlgae's oral delivery technology?
- TransAlgae's oral delivery technology has applications in animal health, replacing antibiotics and injection-based vaccinations with feed supplements containing the desired drug or vaccine. It also includes a proprietary platform for biological-based insecticides for crop protection, targeting specific insects without toxic chemicals.